the ADME Tox specialists
welcome to cyprotex

Ocular Irritation Test

Cyprotex's ocular irritation test service is performed using MatTek’s in vitro 3D human tissue model (EpiOcular™). Cyprotex are a MatTek-approved laboratory for performing these studies.

Contact us to learn more about our ocular testing services.

  • EpiOcular™ is a cornea-like 3D tissue structure that is an in vitro alternative to the Draize Rabbit Eye Test1. The model also allows sub-Draize quantifiable discrimination among mild, milder, and mildest product formulations2.
  • EpiOcular™ is mitotically and metabolically active and releases many of the pro-inflammatory agents (cytokines) known to be important in ocular irritation and inflammation3.
  • EpiOcular™ supports topical testing of undiluted and water-insoluble materials.
  • Cyprotex's ocular irritation test is based upon assessment of the cytotoxicity following exposure to a test agent at three time points. Cytotoxicity is expressed as a decrease in mitochondrial conversion of MTT to formazan.

Contact us to find out more about our ocular irritation testing services.

Related Services
‘A significant advantage of the EpiOcular model is that it can be used to discriminate between the irritation potential of extremely mild products (most cosmetic and personal care products are formulated for inherent mildness).’
2 McCain NE, Binetti RR, Gettings SD, Jones BC (2002) The Toxicologist, 66 (1-S) 243 Soc. of Toxicol. (Reston, VA), Abstract #1191

1Stern M et al., (1998) Evaluation of the EpiOcular™ Tissue Model as an Alternative to the Draize Eye Irritation Test. Toxicology in Vitro 12; 455-461

2 McCain NE et al., (2002) Assessment of ocular irritation ranges of market-leading cosmetic and personal-care products using an in vitro tissue equivalent. The Toxicologist 66 (1-S) 243 Soc. of Toxicol. (Reston, VA), Abstract #1191

3 Thakur A et al., (1997) Modulation of cytokine production from an EpiOcular corneal cell culture model in response to Staphylococcus aureus superantigen. Aust N Z J Ophthalmol 25(4); 43-45.

This website was last updated
on 24th April 2014
This website is intended to assist investors, industry participants, customers and employees to understand Cyprotex’s global operations and ambitions.
Certain information and detail is disclosed in the interest of compliance of AIM Rule 26.